- Home
- MOGU vs BCAB Comparison
MOGU vs BCAB Comparison
Compare MOGU & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOGU | BCAB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 20.8M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOGU | BCAB |
|---|---|---|
| Price | $2.17 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 8.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $0.13 |
| 52 Week High | $8.10 | $1.43 |
Technical Indicators
Market Signals| Indicator | MOGU | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 37.52 |
| Support Level | $2.02 | $0.13 |
| Resistance Level | $2.26 | $0.27 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 10.67 | 28.81 |
Price Performance
Historical ComparisonAbout MOGU MOGU Inc.
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.